Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed Quote. Delayed London Stock Exchange - 11/27 11:39:52 am
7770 GBX   +0.28%
11/27SALESFORCE, DELTA AIR LINES, BEST BUY : Stocks That Defined the Week
DJ
11/27Stocks at record high but yields fall, dollar under pressure
RE
11/27Oil prices post weekly gain ahead of OPEC+ meeting
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Pfizer files COVID-19 vaccine application to U.S. FDA

11/20/2020 | 05:42pm EST
FILE PHOTO: Syringes are seen in front of displayed Biontech and Pfizer logos in this illustration

(Reuters) - Pfizer Inc applied to U.S. health regulators on Friday for emergency use authorization (EUA) of its COVID-19 vaccine, the first such application in a major step toward providing protection against the new coronavirus.

The application to the U.S. Food and Drug Administration (FDA) comes just days after Pfizer and German partner BioNTech SE reported final trial results that showed the vaccine was 95% effective in preventing COVID-19 with no major safety concerns.

Pfizer Chief Executive Officer Albert Bourla confirmed the application had been made in a video posted on the company's website on Friday afternoon.

The FDA said on Friday it would hold a meeting of the advisory committee on Dec. 10 at which members would discuss the vaccine. The agency declined to predict how long its review would take, although both Pfizer and U.S. Health Secretary Alex Azar have said the FDA could authorize the vaccine in mid-December.

Pfizer's shares closed up 1.4% and BioNTech shares ended 9.6% higher in New York, as the possibility of a vaccine soon raised hopes for the end of a pandemic that has claimed more than a quarter of a million lives in the United States and over 1.3 million worldwide.

For an interactive graphic tracking the global spread of COVID-19, open https://graphics.reuters.com/world-coronavirus-tracker-and-maps/ in an external browser.

The application also includes safety data on about 100 children 12-15 years of age. The company said 45% of U.S. trial participants are 56-85 years old.

If the data is solid, "we literally could be weeks away from the authorization of a 95% effective vaccine," Azar said on CBS's "This Morning."

The companies expect the FDA to grant the EUA by mid-December and said they will begin shipping doses almost immediately. Pfizer has said it expects to have 50 million vaccine doses ready this year, enough to protect 25 million people.

The final trial data showed the vaccine provided a similar level of protection across different ages and ethnicities - an encouraging result as the disease disproportionately hurts the elderly and minorities.

Of the 170 volunteers who contracted COVID-19 in Pfizer's trial involving over 43,000 people, 162 had received only a placebo, meaning the vaccine was 95% effective, far higher than originally expected. The U.S. FDA had set minimum bar for efficacy of 50%.

Pfizer said nearly 42% of global participants and 30% of U.S. participants in the Phase 3 study have racially and ethnically diverse backgrounds.

"Filing in the U.S. represents a critical milestone in our journey to deliver a COVID-19 vaccine to the world and we now have a more complete picture of both the efficacy and safety profile of our vaccine," Bourla said in a statement.

Moderna Inc is expected to be the next company to seek a U.S. emergency use nod for a COVID-19 vaccine. An initial analysis of data from its late-stage trial showed the vaccine was 94.5% effective. Final results and safety data are expected in the coming days or weeks.

Both the Pfizer/BioNTech and Moderna vaccines work using a new technology to trigger an immune response known as synthetic messenger RNA that can be produced at scale much more quickly than traditional vaccines.

Of dozens of drugmakers and research institutions racing to develop COVID-19 vaccines, the next late-stage data is expected to come from AstraZeneca Plc, which is working with the University of Oxford, in November or December.

Johnson & Johnson said it expects to have data needed to seek U.S. authorization for its experimental vaccine by February.

(Reporting by Vishwadha Chander in Bengaluru, additional reporting by Ankur Banerjee in Bengaluru, Caroline Humer in New York and Doina Chiacu in Washington; Editing by Bill Berkrot and Matthew Lewis)

By Vishwadha Chander


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.28% 7770 Delayed Quote.2.14%
BIONTECH SE 4.79% 109.99 Delayed Quote.224.65%
MODERNA, INC. 16.35% 127.03 Delayed Quote.549.44%
PFIZER INC. 1.92% 37.23 Delayed Quote.0.30%
All news about ASTRAZENECA PLC
11/27SALESFORCE, DELTA AIR LINES, BEST BU : Stocks That Defined the Week
DJ
11/27Stocks at record high but yields fall, dollar under pressure
RE
11/27Oil prices post weekly gain ahead of OPEC+ meeting
RE
11/27Wall St. gains, Nasdaq hits record high as holiday shopping begins
RE
11/27Nasdaq hits record high as holiday shopping begins
RE
11/27ASTRAZENECA : UK's MHRA Says It Got Health Dept Letter Requesting Review Of Oxfo..
RE
11/27ASTRAZENECA : Will COVID-19 vaccines protect us? Does efficacy equal effectivene..
RE
11/27British midcaps post weekly losses on Brexit woes, dour outlook
RE
11/27EUROPE : European shares rise for fourth straight week; Spain's BBVA jumps
RE
11/27ASTRAZENECA : WHO says it needs to evaluate vaccine candidates on more than just..
RE
More news
Financials (USD)
Sales 2020 26 512 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 43,5x
Yield 2020 2,72%
Capitalization 136 B 136 B -
EV / Sales 2020 5,62x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,49 $
Last Close Price 103,45 $
Spread / Highest target 50,3%
Spread / Average Target 17,4%
Spread / Lowest Target -36,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC2.14%135 908
JOHNSON & JOHNSON-1.28%378 244
ROCHE HOLDING AG-3.47%285 939
NOVARTIS AG-11.58%203 854
PFIZER INC.0.30%203 048
MERCK & CO., INC.-11.97%202 555